This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Westra, J. L. Articles by Plukker, J. T.M. Search for Related Content PubMed PubMed Citation Articles by Westra, J. L. Articles by Plukker, J. T.M.

Determination of TP53 Mutation Is More Relevant Than Microsatellite Instability Status for the Prediction of Disease-Free Survival in Adjuvant-Treated Stage III Colon Cancer Patients

From the Department of Medical Genetics, University of Groningen; Comprehensive Cancer Center North Netherlands; and the Departments of Pathology, Medical Oncology, and Surgery, University Hospital Groningen, the Netherlands

Address reprint requests to John Plukker, MD, PhD, Department of Surgery/Surgical Oncology, University Hospital Groningen, PO Box 30.001, 9700RB, Groningen, the Netherlands; e-mail: j.th.plukker{at}chir.azg.nl

PURPOSE: Microsatellite instability (MSI), TP53 mutation, and KRAS mutation status have been reported as prognostic factors in colon cancer. Most studies, however, have included heterogeneous groups of patients with respect to cancer stage. We determined the prognostic relevance of high-frequency MSI (MSI-H), TP53 mutations, and KRAS mutations in a well-defined group of patients with stage III colon cancer (N = 391), randomly assigned for adjuvant treatment with fluorouracil-based chemotherapy.

METHODS: Three hundred ninety-one tumor specimens were available. MSI was determined in 273 specimens, and mutation analyses of TP53 and KRAS were performed in 220 and 205 specimens, respectively.

RESULTS: In a univariate analysis, MSI-H (44 of 273; 16%) was associated with a longer disease-free survival (DFS; P = .038), but in a multivariate model adjusting for nodal involvement, histology, invasion, and grade of tumor, the association of MSI status with DFS did no longer reach statistical significance, though the risk estimate for microsatellite stability versus MSI-H tumors did not change much. Mutant TP53, found in 116 (53%) of 220 tumors, was associated with a shorter DFS, both in univariate (P = .009) and multivariate analyses (P = .018), whereas KRAS mutations (58 of 205; 28%) did not show any prognostic significance.

CONCLUSION: Both mutant TP53 and MSI-H seem to be prognostic indicators for disease-free survival, but only TP53 retains statistical significance after adjusting for clinical heterogeneity. Thus, in adjuvantly treated patients with stage III colon cancer, presence or absence of a TP53 mutation should be considered as a better predictor for DFS than MSI status.

Supported by a grant from Dutch Cancer Society, NKB number RUG 99-1962.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

This article has been cited by other articles:

				S. Ogino and A. Goel Molecular Classification and Correlates in Colorectal Cancer J. Mol. Diagn., January 1, 2008; 10(1): 13 - 27. [Abstract] [Full Text] [PDF]

				R. Libe, L. Groussin, F. Tissier, C. Elie, F. Rene-Corail, A. Fratticci, E. Jullian, P. Beck-Peccoz, X. Bertagna, C. Gicquel, et al. Somatic TP53 Mutations Are Relatively Rare among Adrenocortical Cancers with the Frequent 17p13 Loss of Heterozygosity Clin. Cancer Res., February 1, 2007; 13(3): 844 - 850. [Abstract] [Full Text] [PDF]

				C. M. van Geelen, J. L. Westra, E. G. de Vries, W. Boersma-van Ek, N. Zwart, H. Hollema, H. M. Boezen, N. H. Mulder, J. T. Plukker, S. de Jong, et al. Prognostic Significance of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand and Its Receptors in Adjuvantly Treated Stage III Colon Cancer Patients J. Clin. Oncol., November 1, 2006; 24(31): 4998 - 5004. [Abstract] [Full Text] [PDF]

				D. Chen, Z. Yu, Z. Zhu, and C. D. Lopez The p53 Pathway Promotes Efficient Mitochondrial DNA Base Excision Repair in Colorectal Cancer Cells. Cancer Res., April 1, 2006; 66(7): 3485 - 3494. [Abstract] [Full Text] [PDF]

				T. Watanabe, T. Kanazawa, Y. Kazama, J. Tanaka, T. Tanaka, S. Ishihara, and H. Nagawa TP53 Mutation and Microsatellite Instability Status for the Prediction of Survival in Adjuvant-Treated Colon Cancer Patients J. Clin. Oncol., December 10, 2005; 23(35): 9031 - 9032. [Full Text] [PDF]

				J. L. Westra, R. M.W. Hofstra, M. Schaapveld, and J. T.M. Plukker In Reply: J. Clin. Oncol., December 10, 2005; 23(35): 9032 - 9033. [Full Text] [PDF]

				E. Van Cutsem and F. Costa Progress in the Adjuvant Treatment of Colon Cancer: Has It Influenced Clinical Practice? JAMA, December 7, 2005; 294(21): 2758 - 2760. [Full Text] [PDF]